Anticancer Drugs Olaparib Oncology Pharmacology Physiotherapy

Olaparib (Description-12)

In this article, we will discuss Olaparib (Description-12). So, let’s get started.

Drug Interactions (3)

In vitro studies have shown that olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Olaparib is predicted to be a weak CYP3A inhibitor in humans. In vitro studies also indicated that olaparib is an inhibitor of UGT1A1, BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K. The clinical relevance of these findings is unknown. In vitro, olaparib is a substrate of, and inhibits, the efflux transporter P-gp. The potential for olaparib to induce P-gp has not been evaluated.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.